Cancer Center News

Dr. Haley Newman, an attending physician with the Cancer Center at Children's Hospital of Philadelphia (CHOP) received the Young Investigator Award from Hyundai Hope on Wheels at a recent ceremony with her peers and patients. She received a $300,000 grant which will aid in vital research for pediatric cancer.

Researchers at Children’s Hospital of Philadelphia revealed insights into optimizing chimeric antigen receptor T cell (CAR-T) therapy for solid pediatric tumors, offering a more complete understanding of how tumor biology and immunological barriers affect efficiency and safety.

Investigators at Children’s Hospital of Philadelphia, St. Jude Children’s Research Hospital, Dana Farber Cancer Institute, and the Children’s Oncology Group, unveiled for the first time that changes in certain genes affect an aggressive cancer, T-cell acute lymphoblastic leukemia, differently depending on genetic ancestry.

John Simpkins, Chief Administrative Officer of the Cancer Center at Children’s Hospital of Philadelphia, is this year’s recipient of the Alex’s Lemonade Stand Pitcher of Hope Award.

Researchers at Children’s Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. Researchers suggest that the findings, published recently in JCO Precision Oncology, could help establish a new standard of care.

Researchers at Children’s Hospital of Philadelphia (CHOP) developed a longitudinal atlas of neuroblastoma, a common and potentially deadly childhood cancer, to gain deeper understanding into precise molecular mechanisms underlying why and how certain treatments eventually become ineffective.

New research from Children’s Hospital of Philadelphia (CHOP) offers insight into how a rare genetic condition called Beckwith–Wiedemann syndrome (BWS) affects the liver and may raise cancer risk.

The 3 South Playroom in CHOP’s Main Building officially reopened after a renovation funded by generous support from Dancing While Cancering, the Maddie Kramer Foundation.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition on December 8.

In a recent study, researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated that children treated for brain tumors face persistent social challenges, including limited friendships and reduced peer acceptance, extending into adulthood. The study is the first to link disruptions in white matter connectivity to impaired social functioning in survivors of pediatric brain tumors.